Biogen's Aduhelm rejected by EMA committee
As expected, the European Medicines Agency's (EMA) special committee, the CHMP, has given a negative opinion on Alzheimer's treatment, Aduhelm, as Biogen proved unable to convince the authority to approve the drug as managed to do in the US.
by marketwire, translated by daniel pedersen
On Friday, Alzheimer's drug Aduhelm, which pharmaceutical firm Biogen is behind, has been rejected by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
